Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)

Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)

Abstract Background Both SARS-CoV-2 mRNA-based vaccines [BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)] have shown high efficacy, with very modest side effects in limiting transmission of SARS-CoV-2 and in preventing the severe COVID-19 disease, characterized by a worrying high occupation of in...

Full description

Bibliographic Details
Main Authors: Maria Antonietta Isgrò, Giusy Trillò, Luigi Russo, Anna Lucia Tornesello, Luigi Buonaguro, Maria Lina Tornesello, Leonardo Miscio, Nicola Normanno, Attilio Antonio Montano Bianchi, Franco Maria Buonaguro, Ernesta Cavalcanti, the anti-COVID-19 INT Task Force
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Infectious Agents and Cancer
Subjects:
Bimodal titer
BNT162b2 (Pfizer-BioNTech)
Antibody avidity
Immunoprotective titer
Online Access:https://doi.org/10.1186/s13027-022-00451-1

Internet

https://doi.org/10.1186/s13027-022-00451-1

Similar Items